Toxic acute tubular necrosis following treatment with zoledronate (Zometa)
Authors:
- Glen S. MarkowitzGMGlen S. Markowitz
- Paul L. FinePFPaul L. Fine
- Jay I. StackJSJay I. Stack
- Cheryl L. KunisCKCheryl L. Kunis
- Jai RadhakrishnanJRJai Radhakrishnan
- Winicjusz PaleckiWPWinicjusz Palecki
- Jin ParkJPJin Park
- Samih H. NasrSNSamih H. Nasr
- Shirley HohSHShirley Hoh
- David S. SiegelDSDavid S. Siegel
- Vivette D. D'AGatiVDVivette D. D'AGati
- 1 July 2003
- journal article
- case report
- Published by Elsevier in Kidney International
- Vol. 64 (1) , 281-289
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2002
- The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget’s disease of boneBone, 2001
- Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development programSeminars in Oncology, 2001
- Zoledronic acid reduces skeletal-related events in patients with osteolytic metastasesCancer, 2001
- Cellular and molecular mechanisms of action of bisphosphonatesCancer, 2000
- The Dysregulated Podocyte PhenotypeJournal of the American Society of Nephrology, 1999
- Renal Tolerability Profile of Novel, Potent Bisphosphonates in Two Short‐Term Rat ModelsBasic & Clinical Pharmacology & Toxicology, 1997
- Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemiaBone and Mineral, 1991
- Foscarnet Nephrotoxicity: Mechanism, Incidence and PreventionAmerican Journal of Nephrology, 1989
- RENAL FAILURE ASSOCIATED WITH INTRAVENOUS DIPHOSPHONATESThe Lancet, 1983